I-Mab ADR (IMAB)

$4.60 +0.33 (7.73%)
Market Cap 357.67M
Revenue (ttm) 0.00
Net Income (ttm) -22.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,077,700
Avg Vol 2,302,170
Day's Range N/A - N/A
Shares Out 81.66M
Stochastic %K 25%
Beta 1.36
Analysts Strong Sell
Price Target $6.50

Company Profile

I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to resear...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 745 6330
Address:
2440 Research Boulevard, Suite 400, Rockville, United States
JarvisFlow
JarvisFlow Sep. 9 at 11:00 AM
BTIG has updated their rating for I-MAB ( $IMAB ) to Buy with a price target of 7.
0 · Reply
JarvisFlow
JarvisFlow Sep. 8 at 3:50 PM
Needham has updated their rating for I-MAB ( $IMAB ) to Buy with a price target of 6.
0 · Reply
Lwschadler
Lwschadler Sep. 2 at 6:24 PM
$IMAB
0 · Reply
CChung
CChung Aug. 28 at 4:09 PM
$IMAB going down to next low? 3.50s??
0 · Reply
jmoralva
jmoralva Aug. 27 at 5:11 PM
$IMAB Now it's doing what was expected, going to $2. That increase didn't make sense.
2 · Reply
FF355
FF355 Aug. 23 at 11:08 AM
$IMAB the math is simple ! Vyloy (zolbe) will do 600m revenue this year. HC.W which give $7 price target to I-mab has only 15m for Givastomig’s first year!
0 · Reply
StockScanners
StockScanners Aug. 22 at 1:49 PM
Current Watchlist🚨 $ELAB $IMAB $EQ $MODV $EEIQ Team lets go
0 · Reply
Stock_Catcher
Stock_Catcher Aug. 22 at 1:36 PM
$IMAB perking
0 · Reply
Szilis793
Szilis793 Aug. 22 at 1:36 PM
$IMAB thats it 😀 Rise like never before 🙏
0 · Reply
dbr_island
dbr_island Aug. 22 at 1:34 PM
$IMAB there it goes DVLT shouldn’t be under $1 imo 🎯✅ Here’s why👇🚨🚨🚨
0 · Reply
Latest News on IMAB
I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee

Aug 25, 2025, 7:00 AM EDT - 15 days ago

I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee

I-Mab to Participate in September Investor Conferences

Aug 21, 2025, 7:00 AM EDT - 19 days ago

I-Mab to Participate in September Investor Conferences

Everest Medicines Expands Strategic Investment in I-MAB

Aug 1, 2025, 8:56 AM EDT - 5 weeks ago

Everest Medicines Expands Strategic Investment in I-MAB

I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares

Aug 1, 2025, 8:00 AM EDT - 5 weeks ago

I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares

I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health

Jul 17, 2025, 7:00 AM EDT - 7 weeks ago

I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

Jul 2, 2025, 11:15 AM EDT - 2 months ago

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research

Jun 30, 2025, 4:01 PM EDT - 2 months ago

I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

Jun 26, 2025, 6:30 AM EDT - 2 months ago

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

I-Mab to Present at Jefferies Global Healthcare Conference

May 20, 2025, 7:00 AM EDT - 4 months ago

I-Mab to Present at Jefferies Global Healthcare Conference

I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Mar 21, 2025, 4:30 PM EDT - 6 months ago

I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

I-Mab Announces Accelerated Givastomig Phase 1b Study Progress

Mar 7, 2025, 7:00 AM EST - 6 months ago

I-Mab Announces Accelerated Givastomig Phase 1b Study Progress

I-Mab to Participate in Leerink Partners Global Healthcare Conference

Feb 18, 2025, 7:00 AM EST - 7 months ago

I-Mab to Participate in Leerink Partners Global Healthcare Conference

I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:30 AM EST - 7 months ago

I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member

Jan 8, 2025, 7:00 AM EST - 8 months ago

I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

Jan 6, 2025, 7:00 AM EST - 8 months ago

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

I-Mab to Participate at the Piper Sandler Healthcare Conference

Nov 21, 2024, 7:00 AM EST - 10 months ago

I-Mab to Participate at the Piper Sandler Healthcare Conference

I-Mab Reports Third Quarter 2024 Results

Nov 14, 2024, 7:00 AM EST - 10 months ago

I-Mab Reports Third Quarter 2024 Results

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

Nov 6, 2024, 7:00 AM EST - 10 months ago

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

Oct 31, 2024, 7:00 AM EDT - 11 months ago

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

Oct 30, 2024, 7:00 AM EDT - 11 months ago

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

I-Mab to Participate at the Truist Securities BioPharma Symposium

Oct 28, 2024, 7:00 AM EDT - 11 months ago

I-Mab to Participate at the Truist Securities BioPharma Symposium

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

Sep 16, 2024, 4:01 PM EDT - 1 year ago

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer

Sep 10, 2024, 7:00 AM EDT - 1 year ago

I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer

I-MAB (IMAB) Q2 2024 Earnings Call Transcript

Aug 28, 2024, 11:50 AM EDT - 1 year ago

I-MAB (IMAB) Q2 2024 Earnings Call Transcript

I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

Aug 28, 2024, 7:00 AM EDT - 1 year ago

I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 7:00 AM EDT - 1 year ago

I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

I-Mab to Release 1H 2024 Financial Results on August 28, 2024

Aug 14, 2024, 7:00 AM EDT - 1 year ago

I-Mab to Release 1H 2024 Financial Results on August 28, 2024

I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)

Aug 7, 2024, 7:00 AM EDT - 1 year ago

I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)

I-Mab Announces Leadership Transitions

Jul 15, 2024, 7:30 AM EDT - 1 year ago

I-Mab Announces Leadership Transitions

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

Jun 5, 2024, 7:00 AM EDT - 1 year ago

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

BMY

I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024

May 23, 2024, 5:05 PM EDT - 1 year ago

I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024

I-Mab to Participate at the Jefferies Global Healthcare Conference

May 22, 2024, 7:00 AM EDT - 1 year ago

I-Mab to Participate at the Jefferies Global Healthcare Conference

I-MAB Filed 2023 Annual Report on Form 20-F

Apr 30, 2024, 7:00 AM EDT - 1 year ago

I-MAB Filed 2023 Annual Report on Form 20-F

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

Apr 5, 2024, 7:00 AM EDT - 1 year ago

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

I-Mab Announces Closing of the Divestiture of Business Operations in China

Apr 2, 2024, 4:01 PM EDT - 1 year ago

I-Mab Announces Closing of the Divestiture of Business Operations in China

I-Mab Reports Full Year 2023 Financial Results and Business Update

Mar 14, 2024, 5:00 PM EDT - 1 year ago

I-Mab Reports Full Year 2023 Financial Results and Business Update

I-Mab: Trading Below Net Cash With Multiple Upside Options

Feb 18, 2024, 3:28 AM EST - 1 year ago

I-Mab: Trading Below Net Cash With Multiple Upside Options

Biotech firm I-Mab to divest China operations, shift focus to US

Feb 7, 2024, 8:36 AM EST - 1 year ago

Biotech firm I-Mab to divest China operations, shift focus to US

I-Mab Signs Agreement to Divest its Assets and Business Operations in China

Feb 7, 2024, 6:00 AM EST - 1 year ago

I-Mab Signs Agreement to Divest its Assets and Business Operations in China

I-Mab Announces Participation at Jefferies and Piper Conferences in November

Nov 6, 2023, 8:00 AM EST - 2 years ago

I-Mab Announces Participation at Jefferies and Piper Conferences in November

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

Nov 1, 2023, 8:00 AM EDT - 2 years ago

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023

Oct 16, 2023, 8:00 AM EDT - 2 years ago

I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503

Oct 10, 2023, 8:00 AM EDT - 2 years ago

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503

AbbVie terminates deal with I-Mab to develop cancer drug

Sep 22, 2023, 5:09 PM EDT - 2 years ago

AbbVie terminates deal with I-Mab to develop cancer drug

ABBV

I-Mab: Why This Company Trades At A Third The Value Of Its Cash

Sep 13, 2023, 4:59 PM EDT - 2 years ago

I-Mab: Why This Company Trades At A Third The Value Of Its Cash

I-Mab Announces Upcoming Participation at September Conferences

Sep 5, 2023, 8:00 AM EDT - 2 years ago

I-Mab Announces Upcoming Participation at September Conferences

I-Mab (IMAB) Q2 2023 Earnings Call Transcript

Aug 17, 2023, 12:26 PM EDT - 2 years ago

I-Mab (IMAB) Q2 2023 Earnings Call Transcript

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

Aug 17, 2023, 6:00 AM EDT - 2 years ago

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023

Aug 8, 2023, 8:00 AM EDT - 2 years ago

I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023

JarvisFlow
JarvisFlow Sep. 9 at 11:00 AM
BTIG has updated their rating for I-MAB ( $IMAB ) to Buy with a price target of 7.
0 · Reply
JarvisFlow
JarvisFlow Sep. 8 at 3:50 PM
Needham has updated their rating for I-MAB ( $IMAB ) to Buy with a price target of 6.
0 · Reply
Lwschadler
Lwschadler Sep. 2 at 6:24 PM
$IMAB
0 · Reply
CChung
CChung Aug. 28 at 4:09 PM
$IMAB going down to next low? 3.50s??
0 · Reply
jmoralva
jmoralva Aug. 27 at 5:11 PM
$IMAB Now it's doing what was expected, going to $2. That increase didn't make sense.
2 · Reply
FF355
FF355 Aug. 23 at 11:08 AM
$IMAB the math is simple ! Vyloy (zolbe) will do 600m revenue this year. HC.W which give $7 price target to I-mab has only 15m for Givastomig’s first year!
0 · Reply
StockScanners
StockScanners Aug. 22 at 1:49 PM
Current Watchlist🚨 $ELAB $IMAB $EQ $MODV $EEIQ Team lets go
0 · Reply
Stock_Catcher
Stock_Catcher Aug. 22 at 1:36 PM
$IMAB perking
0 · Reply
Szilis793
Szilis793 Aug. 22 at 1:36 PM
$IMAB thats it 😀 Rise like never before 🙏
0 · Reply
dbr_island
dbr_island Aug. 22 at 1:34 PM
$IMAB there it goes DVLT shouldn’t be under $1 imo 🎯✅ Here’s why👇🚨🚨🚨
0 · Reply
Stocksman45
Stocksman45 Aug. 22 at 4:10 AM
$IMAB More investor conferences in two weeks… https://www.stocktitan.net/news/IMAB/i-mab-to-participate-in-september-investor-jrw7x1tl6x9h.html
0 · Reply
JarvisFlow
JarvisFlow Aug. 21 at 11:30 AM
HC Wainwright & Co. has updated their rating for I-MAB ( $IMAB ) to Buy with a price target of 7.
0 · Reply
Stocksman45
Stocksman45 Aug. 20 at 6:21 PM
$IMAB on a candlestick chart. Really interesting to see. Long term we know where its going with their blockbuster Givastomab, short term, the chartists can tell us. https://finviz.com/quote.ashx?t=IMAB&p=d
0 · Reply
FF355
FF355 Aug. 18 at 12:08 AM
$IMAB vyloy from Astella , an inferior drug than Giva will achieve 600m sales in its first year with estimate peak sales of 2B. I-mab will not easily license out Giva until Phrase 3 begins. Assuming Giva has peak sales of 2B as well which is conservative. The drug will work 10b( 5 times sales ) 10B divided by 2 which is 5B. I-mab is a $40 drug 28 months from now
1 · Reply
StockScanners
StockScanners Aug. 17 at 7:48 AM
$IMAB reached 5.90
0 · Reply
jmoralva
jmoralva Aug. 15 at 11:28 PM
$IMAB But what do you think? That it will rise non-stop until it reaches $100... It will, but in years. Now, in the next few months, it will correct and return to $2... You fools.
0 · Reply
Ziom
Ziom Aug. 15 at 5:08 PM
$IMAB śmieszy mnie to a później szmaty będą ssać pałę:)
0 · Reply
_www_larval_com_
_www_larval_com_ Aug. 15 at 2:32 PM
$IMAB just turned -3% lower to 6% (~2Mv) in the last few minutes, 08/15 options, follow for more volatility.
0 · Reply
dbr_island
dbr_island Aug. 15 at 2:23 PM
$BSLK $CGTX $SRXH LFG!!!!!!!! 💰💰💰💰💰 ALL PAYING ME HUGE!!!!!! HERZ is another one I have been slowly accumulating 🚢📦📦📦📦📦🚨🚨🚨 $PGEN $IMAB what a day
1 · Reply
Stickygreens97
Stickygreens97 Aug. 15 at 2:06 PM
$IMAB perfect time to short
0 · Reply
MadCrewTrades
MadCrewTrades Aug. 15 at 1:46 PM
$IMAB is there a (short squeeze) group pumping? i can't find any catalyst.
1 · Reply
_www_larval_com_
_www_larval_com_ Aug. 15 at 1:42 PM
$NEGG -8%[-23%] $FUFU -7%[2%] $IMAB 6%[8%] $DARE -6%[5%] $HCTI -5%[10%] most notable movement within the first minutes of trading.
0 · Reply